Shares in Kodiak Sciences nearly tripled on Monday after the US biotech said both of its experimental eye drugs, Zenkuda and tabirafusp-ted (KSI-501), met their main goals in a late-stage trial in wet age-related macular degeneration.
Nearly tripled in one session
Kodiak, listed on Nasdaq under KOD, released topline results from its Phase 3 DAYBREAK study before the US open and held a webcast at 8:30 a.m. New York time. The shares were up 31.9% in pre-market trading, Finviz reported, and kept climbing through the session. The Motley Fool put the day's rise at about 178%.
Before the data, UBS reiterated a buy rating and an $80 price target on the stock, and said it expected Zenkuda to show noninferiority with dosing about every three to three and a half months. The stock's 52-week high before the news was $47.84.
DAYBREAK in three numbers
- 178% approximate one-day rise in Kodiak shares
- 54% of Zenkuda patients on six-monthly dosing after one year
- 0% rate of eye inflammation with Zenkuda in the trial

What DAYBREAK showed
DAYBREAK tested both drugs against aflibercept, the standard injected treatment sold as Eylea, in patients with wet AMD who had not been treated before. Wet AMD is caused by abnormal blood vessels under the retina that leak fluid and can quickly damage central vision.
The main measure was the change in best-corrected visual acuity from the start of the trial to the average of weeks 40, 44 and 48. Both drugs were noninferior to aflibercept, meaning they did at least about as well.
| Zenkuda (tarcocimab tedromer) | Tabirafusp-ted (KSI-501) | Aflibercept | |
|---|---|---|---|
| Dosing after loading | As needed, every 4 to 24 weeks | Every 8 weeks, plus extra doses if needed | Per label |
| Primary goal | Met (P = .0007) | Met (P = .0036) | Comparator |
| Eye inflammation | 0% | 0.4% | Not reported |
| Cataract events | 0.5% | 0% | 0.9% |
Both drugs started with four monthly loading doses. Kodiak said Zenkuda matched or beat aflibercept during that loading phase, but gave no figures. Tabirafusp-ted, which combines IL-6 blocking with a VEGF trap, also met a key anatomical secondary goal, though the reports did not name the measure.
Markets: indices, currencies and commodities
Durability is the selling point
Zenkuda, or tarcocimab tedromer, is an anti-VEGF drug designed to stay in the eye longer. Its average half-life in the human eye is about 20 days, roughly three times that of approved anti-VEGF drugs.
That is why the 54% figure matters. Patients with wet AMD typically need repeated injections into the eye, and stretching the gap to six months would mean far fewer clinic visits. Patients only got another dose when scans showed fluid in the retina, a strict treat-to-dry rule. Chief executive Victor Perlroth said the data "positions us for the next stage of Kodiak's evolution".
There is no direct comparator for the six-month figure in this trial, and the results are company-reported and not yet peer-reviewed.
A comeback after earlier setbacks
The rally reflects how far expectations had fallen. Zenkuda failed an earlier wet AMD trial, DAZZLE, in 2022, when fixed dosing every 12 to 20 weeks did not match aflibercept. Two trials in diabetic macular oedema, GLEAM and GLIMMER, also failed in 2023, with cataracts reported in 19% of Zenkuda patients against 9% on aflibercept.
Since then the company has built a run of positive results. In DAYLIGHT, a 557-patient wet AMD trial, monthly Zenkuda matched aflibercept given every eight weeks. In GLOW2, 62.5% of Zenkuda patients with diabetic retinopathy improved by at least two steps on the severity scale, against 3.3% on sham treatment. It now counts five successful Phase 3 studies across three diseases: DAYBREAK and DAYLIGHT in wet AMD, GLOW1 and GLOW2 in diabetic retinopathy, and BEACON in retinal vein occlusion.
What comes next
- A Biologics License Application for Zenkuda in the fourth quarter of 2026, covering wet AMD, diabetic retinopathy and retinal vein occlusion
- The ALTO Phase 3 trial of tabirafusp-ted in diabetic macular oedema, planned at about 910 patients
- First topline results from KSI-101 in inflammatory macular oedema, expected in December 2026
Kodiak has no approved product yet. Approval is not assured, and the company still has to show that the durability holds up in a second year of data.
Sources
- The Motley Fool: Why Kodiak Sciences skyrocketed today
- Ophthalmology Times: DAYBREAK: tarcocimab, tabirafusp-ted noninferior to aflibercept in wet AMD
- Eyewire News: Kodiak reports Phase 3 DAYBREAK trial meets primary endpoints for Zenkuda in wet AMD
- Finviz: Kodiak Sciences shares rise after DAYBREAK Phase 3 trial results








